Member Info for one4one

Worth a re-post 🍒

Https://thatstocksguy.substack.com/p/helix-exploration-7d7?r=7qyxdp&utm_campaign=post&utm_medium=email&triedRedirect=true

The fluffy final results revealed.

We have raised further equity funds since the year end - firstly £2.5 million on 10 February 2026 and £3 million as recently as 28 April 2026. The purpose of these fundraises is to provide us with sufficient cash resources to finance in full the completion of the Phase I Hello hemo are travelling toward phase 1B and the season where the paper roses will not smell so sweet 🐭

We have raised further equity funds since the year end - firstly £2.5 million on 10 February 2026 and £3 million as recently as 28 April 2026. The purpose of these fundraises is to provide us with sufficient cash resources to finance in full the completion of the Phase I Hello hemo are travelling toward phase 1B and the season where the paper roses will not smell so sweet 🐭

To early to speculate lets wait and see what the results of phase 1b Reveal as the next Adults join the cohort of full dosage, this is where the science Talks !

until then the forum is noise nothing else 🐭

If the adults passed the half dosage/that does not mean the paediatrics can start at the same half dosage as the adults because dosing is weight based in paediatrics the regulators require separate safety data : bottom line : if adults clear a dose level, paediatrics do not automatically ‘eclipse’ or skip ahead. Quick question HG-CT-1 is Autologous and can not be scaled up so will the enrolment be intermittent due to the manufacturing ?.....🐭

The kingdom of heaven the crusaders was defeated and the king of England Quoted, "what does this Victory mean to you " the reply ! To me Nothing to my Army Everything !.....🐭

Give chatbox a whistle india tell it that hemogenyx is not on Aim but is on the Main Market + investors can buy Global stocks and it would be nice to list a full infantry of runners....riders ....&......fallers....show the clean consistent efficacy data....timelines of clinical enrolment Adult/paediatrics Quick Question The Adults passed the half dose safety exercise should the paediatrics eclipse ? or to suffice both evolve @ the same time ps did you write the last Fluffy Rns ?

Yes i agree it is not Aml, what is intriguing is the partnership to manufacture.

CTMC is a co-development accelerator formed through a joint venture between Resilience and UT MD Anderson Cancer Center to fast-track the development and manufacturing of next-generation cell therapies for cancer.

The therapy can be manufactured in approximately three days and delivered to a patient within 11 days. Researchers will evaluate three dose levels to help identify the maximum tolerated dose. A novel BCMA safety switch has been incorporated into the therapy, which can help eliminate the CAR T cells in the event of unexpected side effects

https://www.newswise.com/articles/novel-car-t-cell-therapy-developed-by-ut-md-anderson-researchers-moves-into-clinical-studies 🐭

Hereforhemo post is a balanced assessment of risk and probability 🐭

Https://pharmaphorum.com/news/fda-hands-beone-taiho-approvals-blood-cancers

Note : Oral conception for the older patients with AML

Inqovi as first-line AML therapy

Meanwhile, Otsuka subsidiary Taiho's Inqovi – based on chemotherapy agent decitabine and metabolic inhibitor cedazuridine – has claimed a second FDA approval in combination with Venclexta as an all-oral therapy for newly diagnosed AML in patients aged 75 and over who are unable to tolerate intensive induction chemotherapy.

Taiho said the regimen offers an alternative to parenteral hypomethylating agent–based regimens that require frequent clinic visits in the first-line setting. The approval comes on the back of the phase 2 ASCERTAIN-V study, in which Inqovi/Venclexta achieved a complete remission rate of 41.6%.....🐭

I mentioned CBR....CDX are still in the Petri-dish of which they still are "Fact" HG-CT-1 is the fore runner i grant you that but until the clean efficacy data shows a positive then it a case of No-Mans-Land....Expand your mind & Evolve with the future 🐭

Please enlighten your edited post ; no where in the recent post has the cost of treatment unless you are referring to Autologous "500k " my take is Allogeinic is more cost effective "ball-park figure "20k ! plus of the shelf/accessibility pre-loaded syringes cutting hospital times .....the stage is yours 🐭

In mouse models, the new MSK-developed CAR T cells demonstrated remarkable effectiveness.

They not only eliminated leukaemia in animal models of both adult and paediatric AML, they also created long-lasting protection.

When mice that had been successfully treated were exposed to leukaemia again nearly a year later, they remained cancer-free — a sign their immune systems had effectively learned how to fight the cancer.

Importantly, the treatment spared healthy blood-forming cells, experiments showed.

The researchers also discovered that the new approach shows promise against another leukaemia — B-cell acute lymphoblastic leukaemia (B-ALL), a fast-growing blood cancer where immature B-cells multiply in the bone marrow and blood.

The unusual U5 surface protein was detected in nearly 90% of B-ALL patient samples tested.

In laboratory studies, the CAR T cells effectively targeted B-ALL cells — including those that had lost CD19, the protein targeted by current CAR T cell therapies against this type of leukaemia.

“CD19 loss is a major mechanism of treatment resistance in B-ALL patients who relapse after CD19-directed CAR T cell therapy,” Dr. Abdel-Wahab notes.

“Our approach could potentially address that challenge.”

Based on these promising preclinical results, the research team is now working to advance their new CAR T cells toward clinical trials.

Bottom line : When mice that had been successfully treated were exposed to leukaemia again nearly a year later, they remained cancer-free — a sign their immune systems had effectively learned how to fight the cancer. 🐭

Interesting article although it does not state Autologous or allogenic therapy it does mention healthy donor cells of which is Allogenic of the shelf: cost effective can be scaled up & accessibility this latest Aml therapy is being primed towards clinical trials the mouse models express disease free after 12 months

13 May 2026

Successfully treated AML patients may hold the key to new CAR T cell therapy

Developing effective immunotherapies for acute myeloid leukaemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukaemia cells may also harm the body’s ability to make new, healthy blood cells.

This happens because most of the proteins that can be targeted on the surface of the blood cancer’s cells are also found on vital blood-forming cells.

Now, a team of researchers has developed a new type of CAR T cell therapy that targets a protein found almost exclusively on leukaemia cells and not on healthy cells. Successfully treated AML patients may hold the key to new CAR T cell therapy

13 May 2026

Successfully treated AML patients may hold the key to new CAR T cell therapy

Developing effective immunotherapies for acute myeloid leukaemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukaemia cells may also harm the body’s ability to make new, healthy blood cells.

This happens because most of the proteins that can be targeted on the surface of the blood cancer’s cells are also found on vital blood-forming cells.

Now, a team of researchers from Memorial Sloan Kettering Cancer Centre (MSK) has developed a new type of CAR T cell therapy that targets a protein found almost exclusively on leukaemia cells and not on healthy cells.🐭

Really ok if that suits you fine :-))) ok have a lovely evening ive work to do....🐭

Lets agree to disagree or wait and see @ this point you are not investing but gambling before you release the bloodhounds i sincerely presume hemogenyx are on the scent 🐭

Grt ormond have a trial but not active/enrolling @ present.....hemo are in the early phase before being granted orphan drug destination it all rides on cohort 1B full dose escalation clean efficacy data....🐭

SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as AML

" Note off the shelf.....Allogenic...scaled up....cost effective....Accessibility....there are others in the early stages...🐭

Contempt of court jezza lets Debate microbiology because you bug me ! in the sin bin with a life sentence with no Parole. Bye...bye...🐭

Very romantic the truth the whole truth & nothing but the truth ! yesterday the market was down which effected the bond market plus the country's leadership is un-certain ?..... hemogenyx has acclaimed the half dose safety status with no DLT "obviously" escalating to cohort 1B full dosage

but here lyes the problem no patients have been enrolled so until clean efficacy data ? the science says maybe the market says eventually ps how is the Bollinger's doing Ade ? 🐭